MILAN, Italy, Oct. 13, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Professor Karl Erik Andersson and Professor Roger Bouillon to the Company's Scientific Advisory Board (SAB). Karl Erik Andersson is Professor and Head of Clinical Pharmacology at the University of Lund, Sweden. Recognised across the world as a leader in the pharmacology of the urogenital tract, his research has been fundamental in the understanding and treatment of the most significant urogenital diseases.
Roger Bouillon is Professor and Head of the Laboratory for Experimental Medicine and Endocrinology at the Catholic University of Leuven, Belgium. His research is focused on the hormonal control of bone metabolism and immune response, including the design and evaluation of vitamin D analogues with selective modulating activities potentially applicable to a number of clinical indications.
Together with the current members of BioXell's SAB, Rolf Zinkernagel -- Nobel Laureate for Medicine in 1996 -- Alberto Mantovani and Marco Colonna, all highly renowned immunologists, Professor Andersson and Professor Bouillon will assist BioXell's management in the development of the Company's technologies and projects. Their broad expertise, respectively in the area of urology and Vitamin D, ideally complements BioXell's scientific know-how and will contribute to the Company's R&D programmes in urology and inflammation.
Luciano Adorini, Chief Scientific Officer of BioXell said, "It is BioXell's ambition to have the best people advising the Company on its research strategy. We are therefore extremely pleased that Professor Andersson and Professor Bouillon are joining our SAB as their expertise will add significant value to BioXell's scientific profile."
BioXell is a private biopharmaceutical company focused in the areas of urology and inflammatory disease with offices in Milan, Italy, and Nutley, NJ, USA. Through its two proprietary technology platforms based on Vitamin D3 analogues and TREM receptor biology, BioXell has identified a number of promising lead development programmes. Its pipeline includes a compound, BXL-628 for benign prostatic hyperplasia (currently in Ph II trials) as well as research projects in transplantation, diabetes, sepsis and other urological indications. BioXell has a collaboration with TaiGen Biotechnology (Taiwan) for the research and development of small molecules active against GPCRs in the area of inflammatory diseases. To date, BioXell has raised over Euro 39 million through the participation of world-class VC investors including MPM Capital, Index Ventures, Life Sciences Partners, and NIB Capital Private Equity. BioXell currently employs more than 50 people.
Please click on the link to view formatted press release: http://hugin.info/133681/R/920220/123879.pdf
More information on BioXell can be found on: www.bioxell.com